---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-26-022727"
form_type: "8-K"
ticker: "DYAI"
cik: "0001213809"
company_name: "DYADIC INTERNATIONAL INC"
filed_at: "2026-05-13T20:11:27+00:00"
generated_at: "2026-05-13T22:03:32.331688+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Dyadic Q1 2026 revenue up 182% to $1.11M; net loss narrows to $(0.05)/share

## Summary
- Q1 revenue $1,110,956 vs $393,572 YoY; net loss $(0.05)/share vs $(0.07) prior year.
- Cash and investments $6.6M as of March 31, 2026, down from $8.6M at Dec 31, 2025.
- Received initial purchase orders for recombinant bovine transferrin from cultivated meat customers.
- Proliant Health launched AlbuFree™ DX, with Dyadic entitled to profit share; expanded Fermbox Bio collaboration.
- Signed OEM distribution agreement with IBT Bioservices; advanced Gates Foundation RSV/malaria and CEPI/FBS H5 programs.

## SEC filing metadata
- accession: 0001493152-26-022727
- form_type: 8-K
- ticker: DYAI
- cik: 0001213809
- company_name: DYADIC INTERNATIONAL INC
- filed_at: 2026-05-13T20:11:27+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1213809/000149315226022727/0001493152-26-022727-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1213809/000149315226022727/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-26-022727
- JSON: https://secwatch.observer/filing/0001493152-26-022727.json
- Plain text: https://secwatch.observer/filing/0001493152-26-022727.txt

## Key facts
- Earnings Releases
  DYADIC INTERNATIONAL INC reported financial results for Q1 2026.
  - Period: Q1 2026
  - Result: reported results
  source text: Dyadic International, Inc. (“Dyadic”) issued a press release announcing its results for the quarter ended March 31, 2026.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1213809/000149315226022727/0001493152-26-022727-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.